GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aerovate Therapeutics Inc
Shares of Aerovate, a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension, are driven by expectations for clinical trials. The chart reflects the potential of its product to be a breakthrough in the treatment of this serious condition.
Share prices of companies in the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. We have classified it in the Pharma: Immunology group. The chart below shows how investors value companies offering new approaches to treating rare diseases.
Broad Market Index - GURU.Markets
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
JBIO - Daily change in the company's share price Aerovate Therapeutics Inc
For Aerovate, a biopharmaceutical company, change_co is a measure of reaction to clinical and regulatory news. Daily fluctuations reflect the volatility associated with the development of lung drugs. This metric is a key element in the analysis of young biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Aerovate Therapeutics, Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with JBIO, which focuses on treating pulmonary hypertension, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Aerovate Therapeutics is a biopharmaceutical company specializing in drugs for the treatment of respiratory diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Aerovate's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aerovate Therapeutics Inc
For Aerovate Therapeutics, the year-over-year trend is a story about developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its 12-month market cap depends entirely on clinical trial data. The success of its innovative approach could fundamentally change the standard of treatment for this serious condition.
Annual dynamics of market capitalization of the market segment - Pharma immune
Aerovate Therapeutics is a clinical-stage biotech developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aerovate Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aerovate Therapeutics Inc
Aerovate's performance as a biopharmaceutical company will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news on the progress of clinical trials of its inhaled drug for the treatment of pulmonary hypertension.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Aerovate Therapeutics develops drugs to treat rare lung diseases. This biotech segment is characterized by high risks, but also enormous potential if successful. The chart below shows the overall investor sentiment toward companies working in pulmonary hypertension and their belief in new therapeutic approaches.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aerovate Therapeutics is a biopharmaceutical company developing treatments for rare lung diseases. Like other clinical-stage biotechs, its stock price is driven not by the market but by research progress. It's a high-risk bet on the success of a specific scientific approach.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aerovate Therapeutics Inc
Shares of Aerovate Therapeutics, a clinical-stage biopharmaceutical company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials for their drug for the treatment of pulmonary arterial hypertension. The chart below illustrates how short-term scientific events can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma immune
How does Aerovate Therapeutics' performance compare to the broader biotech sector? This chart compares the company's weekly stock price movements with the overall trend. This helps us understand whether the move, driven by news about a pulmonary hypertension treatment, is a unique event or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aerovate Therapeutics is a biopharmaceutical company focused on treating rare lung diseases. This chart shows how out of sync its weekly performance is with the broader market. Its stock price is driven solely by news about clinical trials, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
JBIO - Market capitalization of the company Aerovate Therapeutics Inc
Aerovate Therapeutics' valuation on the chart represents a concentrated bet on its inhaled drug for the treatment of pulmonary arterial hypertension. This clinical-stage biotech's market cap is entirely dependent on the success of this single asset's trials. The dynamics clearly illustrate the binary outcome: breakthrough or failure.
JBIO - Share of the company's market capitalization Aerovate Therapeutics Inc within the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company whose market share is based on the development of an inhaled drug for the treatment of pulmonary arterial hypertension. Its market capitalization reflects the potential of its product to become a more convenient alternative to existing therapies.
Market capitalization of the market segment - Pharma immune
The chart below is a barometer of the biotech sector focused on treating pulmonary hypertension. Aerovate Therapeutics, with its inhaled drug, is an innovator. The dynamics in the chart reflect the hopes associated with the development of more convenient and effective treatments.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with pulmonary hypertension. Aerovate Therapeutics' market capitalization reflects investors' faith in its innovative inhaled drug. The line shows how this biotechnology, aimed at improving quality of life, is generating enormous potential value in global medicine.
Book value capitalization of the company, segment and market as a whole
JBIO - Book value capitalization of the company Aerovate Therapeutics Inc
Aerovate Therapeutics, a clinical-stage company, derives its book value from its scientific potential. The chart below reflects the financial valuation of its intellectual property for an inhaled drug for the treatment of pulmonary arterial hypertension. The dynamics demonstrate how the company is investing in the development of its core asset.
JBIO - Share of the company's book capitalization Aerovate Therapeutics Inc within the market segment - Pharma immune
For Aerovate Therapeutics, a clinical-stage biopharmaceutical company, its tangible assets are limited to laboratories and offices. The chart shows its modest share of physical infrastructure, emphasizing that its primary value at this stage lies in the intellectual property of its innovative drug.
Market segment balance sheet capitalization - Pharma immune
Below you can see the overall book value of the pharmaceutical sector. Compared to this, Aerovate, which is developing a drug to treat pulmonary hypertension, looks "light." Its value lies in its patents and clinical trial data, not in its large manufacturing plants.
Book value of all companies included in the broad market index - GURU.Markets
Aerovate Therapeutics is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. The company's assets are not its factories, but rather the patent for the drug and clinical trial data. The company's balance sheet is the value of the hope for a new, more convenient treatment for this serious condition.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aerovate Therapeutics Inc
Aerovate's balance sheet is its cash and patent. Its market capitalization is its bet on the success of its inhalation drug. The MvsBCap_Co chart shows how many times the "hope" for a new, more convenient drug could be worth compared to the company's cash in hand.
Market to book capitalization ratio in a market segment - Pharma immune
Aerovate Therapeutics is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its value lies in this single product. The chart shows a high speculative valuation by the market, which is awaiting clinical trial results.
Market to book capitalization ratio for the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its value lies in the potential of its lead drug candidate. This chart illustrates why clinical-stage biotech companies can enjoy high valuations long before they reach profitability.
Debts of the company, segment and market as a whole
JBIO - Company debts Aerovate Therapeutics Inc
Aerovate Therapeutics (JBIO), a biopharmaceutical company, is using debt to finance the development of its drug for pulmonary arterial hypertension. This chart shows how the company is raising capital to conduct expensive clinical trials. In this field, debt is a critical resource for advancing a potentially life-saving drug.
Market segment debts - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company focused on developing an inhaled drug for the treatment of pulmonary arterial hypertension. Developing drugs for rare diseases is a long and risky process. This chart shows how the company funds its expensive clinical-stage research in this complex area.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aerovate Therapeutics Inc
Aerovate Therapeutics is a biopharmaceutical company developing drugs to treat lung diseases. This chart shows its reliance on debt financing to conduct clinical trials. For a company focused on a single drug candidate, high debt represents a binary risk: either massive success or a complete loss of investment.
Market segment debt to market segment book capitalization - Pharma immune
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. Financing late-stage trials is very expensive. The chart shows how the company's debt load relates to the market capitalization and risk of the overall biotech sector.
Debt to book value of all companies in the market
Aerovate Therapeutics (JBIO) is a clinical-stage biopharmaceutical company developing a drug to treat pulmonary arterial hypertension. This chart shows the overall level of debt in the economy. It clearly illustrates why companies like JBIO rely solely on equity capital during expensive clinical trials.
P/E of the company, segment and market as a whole
P/E - Aerovate Therapeutics Inc
This chart for Aerovate Therapeutics, a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension, is a measure of hope. There is no price-to-earnings ratio. The company's valuation is based on the potential of its drug to become a more convenient and effective alternative to existing treatments.
P/E of the market segment - Pharma immune
This chart illustrates the average P/E ratio for biotech companies. For Aerovate, which is developing a drug to treat a rare lung disease, it serves as a backdrop. It shows the overall level of investor confidence in the sector, providing context for Aerovate's valuation, which is betting on the success of its single key drug.
P/E of the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Their approach aims to improve drug delivery directly to the lungs. This risk appetite chart helps understand how investors evaluate companies offering new treatments for serious diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aerovate Therapeutics Inc
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension (PAH). This schedule reflects the expectations for this new, more convenient treatment for this rare and severe disease. The evaluation is entirely dependent on the success of the drug in clinical trials and its potential advantage over existing therapies.
%20P%2FE%20Aerovate%20Therapeutics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aerovate-Therapeutics-Inc&v=1772657145319 "Chart of the company's future (projected) P/E Aerovate Therapeutics Inc")
Future (projected) P/E of the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart reflects the company's long-term profitability expectations and shows how the market perceives their drug's potential to offer patients a more convenient and effective treatment option.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772657145332 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its value depends almost entirely on the success of this single product. This market expectations chart reflects investor willingness to invest in biotech companies with a binary outcome (win or lose).
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772657145352 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aerovate Therapeutics Inc
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension, a rare and severe disease. Its financial success is entirely dependent on the results of clinical trials and subsequent approval of this single product candidate.
Profit of companies in the market segment - Pharma immune
Aerovate Therapeutics is developing a drug to treat a rare and severe disease, pulmonary arterial hypertension. The company is in clinical trials. This chart for the biotech sector illustrates how focusing on orphan diseases can be a commercially attractive strategy, impacting the overall profitability of the industry.
Overall market profit
Aerovate Therapeutics is a clinical-stage biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its future depends entirely on the success of clinical trials. The company's value is determined by scientific data, not the macroeconomic indicators that shape this graph.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aerovate Therapeutics Inc
Aerovate Therapeutics is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This graph reflects expectations, which are entirely dependent on the success of its clinical trials. The potential to offer a more convenient and effective treatment is the main driver for analysts' forecasts.
%20profit%20of%20the%20company%20Aerovate%20Therapeutics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aerovate-Therapeutics-Inc&v=1772657145377 "Graph of future (projected) profit of the company Aerovate Therapeutics Inc")
Future (predicted) profit of companies in the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart shows the revenue forecast for the immunopharmaceutical sector. It reflects expected demand for new, more convenient treatments for rare diseases. This context is important for assessing the commercial potential of Aerovate's product.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772657145381 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. As a clinical-stage company, it is entirely dependent on research and investment. The overall economic climate, reflected in this chart, determines investor risk appetite and the availability of capital for biotech startups.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772657145392 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aerovate Therapeutics Inc
Aerovate Therapeutics is a clinical-stage biotech company developing an inhaled drug for the treatment of a rare and serious condition, pulmonary arterial hypertension. This chart shows how investors view the potential of its lead product, which could offer a more convenient and effective treatment option.
P/S market segment - Pharma immune
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing AV-101, an inhaled treatment for pulmonary arterial hypertension (PAH). This drug targets the cause of the disease, not just the symptoms. This chart shows the average market valuation for the sector, helping to understand how the market views the potential of this new approach to PAH treatment.
P/S of the market as a whole
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. The inhaled formulation may offer advantages over existing treatments. This market valuation chart helps understand the premium investors are paying for this potentially disruptive, yet risky, revenue stream.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aerovate Therapeutics Inc
Aerovate Therapeutics is a biopharmaceutical company developing a drug to treat pulmonary arterial hypertension. Without revenue, it is valued based on its future potential. This chart reflects investor expectations for the success of its clinical trials and the commercialization of the product.
%20P%2FS%20Aerovate%20Therapeutics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aerovate-Therapeutics-Inc&v=1772657145438 "The graph of the company's future (projected) P/S Aerovate Therapeutics Inc")
Future (projected) P/S of the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart compares market expectations for its future revenue with those of other immune pharma companies. The valuation reflects investor expectations for its lead candidate and its potential to improve patients' lives.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772657145459 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Aerovate Therapeutics is developing a drug to treat a rare disease, pulmonary arterial hypertension. It is a highly specialized biotechnology company. Market optimism, as seen in this chart, is important for companies like this, as it provides access to the capital needed to conduct expensive clinical trials that could save patients' lives.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772657145481 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aerovate Therapeutics Inc
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. At this stage, its revenue comes from funding, not sales. The chart below reflects the financial flows that enable the company to conduct expensive clinical trials of its lead candidate.
Sales of companies in the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company focused on developing a single product, AV-101, for the treatment of pulmonary arterial hypertension. This inhaled drug has the potential to become a new standard of care. Currently, there are no revenues. This chart shows the potential of the rare lung disease market, where a successful drug could become a blockbuster.
Overall market sales
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. Its future depends entirely on the success of clinical trials. The connection to this timeline is indirect: the overall state of the economy affects the availability of capital to fund expensive R&D projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aerovate Therapeutics Inc
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension (PAH). The inhaled formulation may offer advantages over existing treatments. This graph reflects analyst expectations for the success of clinical trials and the drug's commercial potential.
%20sales%20of%20the%20company%20Aerovate%20Therapeutics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aerovate-Therapeutics-Inc&v=1772657145565 "Schedule of future (projected) sales of the company Aerovate Therapeutics Inc")
Future (projected) sales of companies in the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart shows the overall outlook for the immunopharmaceutical sector. It allows us to assess whether a more convenient inhaled drug delivery method could offer patients a significant advantage over existing treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772657145577 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. This chart, reflecting the investment climate in biotech, is important for the company. Like many companies in clinical development, Aerovate relies on its ability to raise capital to fund its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772657145635 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aerovate Therapeutics Inc
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of a rare and serious condition—pulmonary arterial hypertension. Its core business is focused clinical trials. This chart reflects the costs of developing a product that has the potential to significantly improve patients' quality of life.
Market segment marginality - Pharma immune
Aerovate Therapeutics is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Their goal is to offer a more convenient and effective treatment option. This graph reflects their investment in clinical trials of this promising therapy, which could be highly profitable if successful.
Market marginality as a whole
Aerovate Therapeutics is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. The overall picture of profitability is irrelevant for them. Their future depends entirely on the success of their lead candidate in clinical trials. It's a classic biotech story with a binary outcome: breakthrough or failure.
Employees in the company, segment and market as a whole
Number of employees in the company Aerovate Therapeutics Inc
Aerovate Therapeutics is a biotech company developing a drug to treat pulmonary arterial hypertension. This graph shows a small, focused team. A small team is typical for a clinical-stage company, where all resources are focused on advancing the lead candidate.
Share of the company's employees Aerovate Therapeutics Inc within the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart shows its market share in the narrow cardiopulmonary care niche. It reflects the company's and its team's focus on creating a more convenient and potentially more effective treatment for this serious condition.
Number of employees in the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart shows employment in the pharmaceutical development sector. The growing number of scientists and clinicians reflects progress in clinical trials and the hope of creating a more convenient and effective treatment for this serious condition.
Number of employees in the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension, a serious condition with limited treatment options. This chart, which shows the overall labor market, highlights the depth of innovation in modern medicine and the demand for highly specialized talent.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aerovate Therapeutics Inc (JBIO)
Aerovate Therapeutics Inc. is a biopharmaceutical company developing a drug to treat pulmonary arterial hypertension. Its valuation is based entirely on the potential of a single product. This chart illustrates a model with a very high market capitalization per employee. Investors are assessing the future sales of this drug, which is being developed by a small, focused team.
%20of%20the%20company%20Aerovate%20Therapeutics%20Inc%20(JBIO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aerovate-Therapeutics-Inc-JBIO&v=1772657145896 "Chart of market capitalization per employee (in thousands of dollars) of the company Aerovate Therapeutics Inc (JBIO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. It has a highly focused approach. The chart shows how the market views the potential of its single key candidate. The high per-employee price reflects investor hopes for a breakthrough in the treatment of this rare disease.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772657145984 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension, a highly specific and severe condition. This chart shows a high market value per employee, reflecting investor hopes that their drug will become a new standard of treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772657145992 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aerovate Therapeutics Inc (JBIO)
Aerovate Therapeutics (JBIO) is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This is R&D. This chart shows the "cost" of developing this niche drug—the negative profit (expenses) per scientist involved in clinical trials.
%20Chart%20Aerovate%20Therapeutics%20Inc%20(JBIO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aerovate-Therapeutics-Inc-JBIO&v=1772657146006 "Company Profit Per Employee (in thousands of dollars) Chart Aerovate Therapeutics Inc (JBIO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Aerovate Therapeutics (JBIO) is developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension. Their business is R&D. This chart shows the benchmark for biotech staff efficiency. It's important for assessing how effectively Aerovate's scientific team utilizes investor capital.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772657146062 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Aerovate Therapeutics (JBIO) is a clinical-stage biotech company focused on the treatment of pulmonary arterial hypertension. Their lead candidate is an inhaled form of imatinib. This is R&D. The graph shows the investment (negative return) per employee required to conduct expensive clinical trials of this drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772657146100 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aerovate Therapeutics Inc (JBIO)
Aerovate Therapeutics is a biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. This chart reflects its clinical status. No revenue per employee is normal for a company focused on clinical trials of a single promising candidate.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aerovate-Therapeutics-Inc-JBIO&v=1772657146117 "Sales chart per company employee Aerovate Therapeutics Inc (JBIO)")
Sales per employee in the market segment - Pharma immune
Aerovate Therapeutics (JBIO) is a clinical-stage biotech developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension. This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform in this specific niche.
Sales per employee for the market as a whole
Aerovate Therapeutics (JBIO) is a biotech company focused on a single product (AV-101) for the treatment of pulmonary arterial hypertension. It's an inhaled form of the drug. They're a clinical-stage R&D company with no revenue. This graph (close to zero) reflects their investment in research: their research staff is working on this single, but potentially major, project.
Short shares by company, segment and market as a whole
Shares shorted by company Aerovate Therapeutics Inc (JBIO)
Aerovate Therapeutics is a biotech company developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension. This chart shows bearish bets. "Shorting" a clinical-stage biotech is a bet that their drug will fail trials, showing no efficacy or causing side effects.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aerovate-Therapeutics-Inc-JBIO&v=1772657146140 "Short Shares Chart for the Company Aerovate Therapeutics Inc (JBIO)")
Shares shorted by market segment - Pharma immune
Aerovate Therapeutics (JBIO) is a clinical-stage biotech developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension. This chart is a barometer of sentiment across the entire biotech industry. If investors are shorting a sector, they don't believe risky R&D will succeed. For Aerovate, which relies on capital, this signals a "venture drought."
Shares shorted by the overall market
Aerovate Therapeutics is a clinical-stage biotech company. Its success depends on trial data, not economic cycles. However, when this chart shows peak market pessimism, raising capital—JBIO's lifeblood—becomes extremely difficult. Risk-off sentiment freezes funding, threatening long-term development plans.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aerovate Therapeutics Inc (JBIO)
Aerovate Therapeutics (JBIO) is a clinical-stage biotech. Shares are highly sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold levels (<30) often reflect research setbacks or a general aversion to risk in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aerovate-Therapeutics-Inc-JBIO&v=1772657146224 "RSI 14 indicator chart for the company's stock Aerovate Therapeutics Inc (JBIO)")
RSI 14 Market Segment - Pharma immune
Aerovate Therapeutics (JBIO) is a biotech company focused on the treatment of pulmonary arterial hypertension (PAH). Its lead candidate is an innovative inhaled drug. This chart shows the overall sentiment in the immunology and pulmonary disease biotech sector. It helps separate JBIO's performance from the general biotech hype.
RSI 14 for the overall market
Aerovate Therapeutics (JBIO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast JBIO (Aerovate Therapeutics Inc)
Aerovate Therapeutics (JBIO) is a biopharmaceutical company developing AV-101, an inhaled drug for the treatment of pulmonary arterial hypertension (PAH). This chart shows the average analyst price target, which is almost entirely based on their assessment of the likelihood of clinical trial success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-JBIO-Aerovate-Therapeutics-Inc&v=1772657146347 "A chart showing analyst consensus forecasts for the expected stock price. JBIO (Aerovate Therapeutics Inc)")
The difference between the consensus estimate and the actual stock price JBIO (Aerovate Therapeutics Inc)
Aerovate (JBIO) is a clinical-stage biotech focused on a single disease: pulmonary arterial hypertension (PAH). Its lead is AV-101, an inhaled version of an older drug. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the success of this single drug's clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-JBIO-Aerovate-Therapeutics-Inc&v=1772657146348 "A chart showing the difference between the consensus forecast and the actual stock price. JBIO (Aerovate Therapeutics Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Aerovate (JBIO) is a biotech focused on the treatment of pulmonary arterial hypertension (PAH). The company is developing an innovative inhaled drug (AV-101), which could become a convenient alternative to complex infusions. This chart shows analysts' overall expectations across the immunopharma sector, reflecting whether experts believe in the success of new drug delivery methods.
Analysts' consensus forecast for the overall market share price
Aerovate is a clinical-stage biotech company (focused on lung diseases). It's a risky R&D play. This chart of overall market sentiment is important. Optimism = the market is willing to burn money funding unprofitable biotechs with high potential. Pessimism = risk aversion, and capital for R&D (like JBIO's) dries up.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aerovate Therapeutics Inc
Aerovate (JBIO) is a clinical-stage biotech focused on a single target: pulmonary arterial hypertension (PAH). Their selling point is an inhaled (rather than oral) formulation of a well-known drug (Imatinib). This graph represents a binary R&D bet. Its valuation reflects the market's belief that their delivery method (inhalation) will prove effective and safe in clinical trials.
AKIMA Market Segment Index - Pharma immune
Aerovate Therapeutics (JBIO) is a clinical-stage biotech developing a drug (AV-101) for the treatment of pulmonary arterial hypertension. This chart shows the average index for the immunopharmaceutical sector. It provides investors with a benchmark for how Aerovate's performance compares to the sector average for companies pursuing scientific breakthroughs.
The AKIM Index for the overall market
Aerovate Therapeutics is a biotech company developing treatments for rare cardiovascular diseases (pulmonary hypertension). This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this clinical case following recent trial results.
